What is the most effective contraceptive option for a woman with adenomyosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Best Birth Control for Adenomyosis

The levonorgestrel-releasing intrauterine system (LNG-IUD) is the most effective contraceptive option for women with adenomyosis, providing superior symptom control while offering highly effective contraception.

Primary Recommendation: LNG-IUD

The LNG-IUD stands out as the optimal choice because it directly addresses both contraceptive needs and adenomyosis-related symptoms through local progestin delivery. Research demonstrates that the LNG-IUD significantly improves:

  • Heavy menstrual bleeding - dramatically reduced compared to copper IUD
  • Dysmenorrhea - substantial pain reduction
  • Hemoglobin levels - improved anemia outcomes
  • Overall side effect profile - significantly lower than copper IUD (except for acne) 1

The LNG-IUD provides continuous local progestin exposure that suppresses endometrial and adenomyotic tissue growth while maintaining highly effective contraception with minimal systemic effects.

Alternative Hormonal Options (If LNG-IUD Not Suitable)

Second-Line: Etonogestrel Implant

The subcutaneous etonogestrel implant is an excellent alternative, particularly for women who cannot tolerate or prefer to avoid an intrauterine device. Clinical data shows significant improvements after 12 months:

  • Dysmenorrhea VAS score: decreased from 7.62 to 1.45
  • Hemoglobin: increased from 94.54 to 127.08 g/L
  • Uterine volume: reduced from 198.53 to 118.03 cm³
  • Serum CA125: decreased from 100.41 to 34.58 U/mL 2

Important caveat: Expect changes in bleeding patterns and potential amenorrhea, which some patients find acceptable while others may not tolerate.

Third-Line: Combined Hormonal Contraceptives (CHCs)

CHCs used in continuous or extended regimens (not cyclic) provide both contraception and symptom management. The 2024 CDC guidelines recognize CHCs as appropriate options 3. However, dienogest (a progestin-only option not primarily marketed as contraception in the US) shows superior efficacy compared to standard COCs for adenomyosis symptoms 4.

For CHC users experiencing breakthrough bleeding, the guidelines recommend against hormone-free intervals more than once monthly as this reduces contraceptive effectiveness 3.

Fourth-Line: Progestin-Only Pills (POPs)

Continuous progestin-only pills (desogestrel 75 mcg or drospirenone 4 mg) can manage symptoms, though long-term data shows:

  • Desogestrel has higher discontinuation rates due to reduced long-term efficacy
  • Drospirenone effectively manages heavy bleeding and dysmenorrhea
  • Both require daily compliance 5

Fifth-Line: DMPA (Depot Medroxyprogesterone Acetate)

Injectable DMPA every 3 months is recognized as an appropriate option 3, though less data exists specifically for adenomyosis compared to LNG-IUD or implants.

What to Avoid

Copper IUD (Cu-IUD): This is contraindicated for adenomyosis management. Studies show it significantly worsens menstrual bleeding and dysmenorrhea compared to LNG-IUD, directly exacerbating adenomyosis symptoms 1.

Clinical Algorithm

  1. First choice: Offer LNG-IUD unless contraindications exist (current PID, uterine anomalies preventing insertion, or patient preference against IUD)

  2. If IUD declined/contraindicated: Offer etonogestrel implant with counseling about bleeding pattern changes

  3. If long-acting methods declined: Offer continuous CHCs (extended/continuous regimen, not cyclic)

  4. If estrogen contraindicated: Offer continuous POPs (drospirenone preferred over desogestrel for long-term use)

  5. If daily pills not feasible: Consider DMPA injections

Key Counseling Points

  • Bleeding changes are expected with all progestin-based methods but typically improve symptoms overall
  • Long-term management is necessary as adenomyosis is a chronic condition requiring sustained treatment 5
  • Symptom improvement typically takes 3-6 months to fully manifest
  • Flexibility exists to switch between progestin formulations or routes if side effects occur 5
  • For women desiring future fertility, GnRH agonist pre-treatment may be beneficial before conception attempts, but this is not a contraceptive option 6

Common Pitfalls

  • Prescribing cyclic rather than continuous hormonal regimens - this reduces efficacy for adenomyosis
  • Choosing copper IUD thinking "any IUD works" - copper IUD worsens adenomyosis symptoms
  • Discontinuing effective treatment too early due to initial irregular bleeding before allowing 3-6 months for stabilization
  • Not counseling about expected amenorrhea with progestin methods, leading to unnecessary discontinuation

References

Research

Treatment of Adenomyosis with Subcutaneous Etonogestrel Implants: A Clinical Observational Study in 17 Patients.

Medical science monitor : international medical journal of experimental and clinical research, 2018

Guideline

u.s. selected practice recommendations for contraceptive use, 2024.

MMWR Recommendations and Reports, 2024

Research

Comparison of dienogest versus combined oral contraceptive pills in the treatment of women with adenomyosis: A randomized clinical trial.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2021

Research

Medical treatment for adenomyosis: long term use of progestins.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.